Pw Medtech Group Ltd

recently revealed that they own a 16.7% stake in China Biologic Products Holdings, Inc. (NASDAQ:CBPO) in a Form 13D disclosure that was filed with the SEC on Wednesday, January 10th. The investor owns 5,521,000 shares of the stock worth approximately $454,599,140. The reporting parties listed on the disclosure included PW Medtech Group Limited, Cross Mark Limited and Liu Yufeng. The filing is available through the SEC website at this link.

Several other institutional investors and hedge funds have also added to or reduced their stakes in CBPO. Legal & General Group Plc raised its holdings in shares of China Biologic Products by 41.2% during the third quarter. Legal & General Group Plc now owns 2,966 shares of the biopharmaceutical company’s stock valued at $274,000 after buying an additional 865 shares during the last quarter. Cubist Systematic Strategies LLC raised its holdings in shares of China Biologic Products by 73.2% during the third quarter. Cubist Systematic Strategies LLC now owns 4,617 shares of the biopharmaceutical company’s stock valued at $426,000 after buying an additional 1,952 shares during the last quarter. State of New Jersey Common Pension Fund D bought a new stake in shares of China Biologic Products during the third quarter valued at approximately $439,000. Strs Ohio bought a new stake in shares of China Biologic Products during the third quarter valued at approximately $664,000. Finally, JPMorgan Chase & Co. bought a new stake in shares of China Biologic Products during the third quarter valued at approximately $795,000. 65.13% of the stock is currently owned by institutional investors.

China Biologic Products Holdings, Inc. (NASDAQ CBPO) opened at $82.34 on Wednesday. China Biologic Products Holdings, Inc. has a 12 month low of $72.21 and a 12 month high of $120.46. The company has a market cap of $2,630.00, a P/E ratio of 21.44, a P/E/G ratio of 1.00 and a beta of 1.79.

CBPO has been the topic of a number of recent analyst reports. Zacks Investment Research raised China Biologic Products from a “sell” rating to a “hold” rating in a report on Wednesday, November 15th. BidaskClub upgraded shares of China Biologic Products from a “strong sell” rating to a “sell” rating in a research note on Wednesday, December 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. China Biologic Products has an average rating of “Hold” and an average target price of $137.50.

TRADEMARK VIOLATION WARNING: “Pw Medtech Group Ltd Declares Ownership of 16.7% Stake in China Biologic Products Holdings, Inc. (CBPO)” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/pw-medtech-group-ltd-declares-ownership-of-16-7-stake-in-china-biologic-products-holdings-inc-cbpo/1801231.html.

China Biologic Products Company Profile

Want to see what other hedge funds are holding CBPO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for China Biologic Products Holdings, Inc. (NASDAQ:CBPO).

Institutional Ownership by Quarter for China Biologic Products (NASDAQ:CBPO)

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.